Gilead Sciences (GILD) Appears More Optimistic About Descovy During NDR - RBC

September 19, 2019 6:42 AM
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $91.00 price target on Gilead Sciences (NASDAQ: GILD) after taking ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments